查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1785231

癌症疫苗市場－全球產業規模、佔有率、趨勢、機會和預測，按適應症類型、疫苗類型、技術類型、地區和競爭細分，2020-2030 年

Cancer Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication Type, By Vaccine Type, By Technology Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球癌症疫苗市場價值為 83.2 億美元，預計在預測期內將達到 141.5 億美元，到 2030 年的複合年成長率為 9.21%。癌症疫苗是一種免疫療法，旨在刺激免疫系統識別和攻擊癌細胞。與預防傳染病的傳統疫苗不同，癌症疫苗旨在透過利用人體自身的免疫反應來治療或預防癌症。癌症疫苗背後的概念是向免疫系統呈現癌細胞表面的特定分子或抗原。這些抗原通常是癌細胞獨有的，或在癌細胞上的含量比正常細胞更高。透過讓免疫系統接觸這些抗原，目標是讓免疫細胞能夠辨識和摧毀癌細胞，同時保護健康細胞。

市場概覽
預測期 2026-2030
2024年市場規模 83.2億美元
2030年市場規模 141.5億美元
2025-2030 年複合年成長率 9.21%
成長最快的領域 重組癌症疫苗
最大的市場 北美洲

免疫療法（包括免疫檢查點抑制劑和 CAR-T 細胞療法）的成功，激發了人們對癌症疫苗潛力的興趣和信心。這些進步凸顯了免疫系統在靶向癌細胞中的作用，推動了對癌症疫苗的進一步研究和投資。基因組學、蛋白質組學和生物資訊學的進步使我們對腫瘤生物學有了更深入的了解，並能夠識別潛在的疫苗標靶。這些技術創新加速了癌症疫苗的發現和發展。將疫苗與免疫檢查點抑制劑或化療相結合等不同治療方式的概念已獲得關注。聯合療法有可能提高治療效果並克服抗藥性機制。各種全球健康組織和計劃都強調了癌症預防和治療的重要性。這些計劃有助於提高人們對癌症疫苗研發的認知並增加資金。

關鍵市場促進因素

免疫檢查點抑制劑的需求不斷成長

主要市場挑戰

癌症免疫學的複雜性

主要市場趨勢

合作與夥伴關係

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成的臨床試驗
  • 終止臨床試驗
  • 按開發階段分類的管道
  • 管道狀況細分
  • 按研究類型細分的研發管線
  • 各地區管道分佈
  • 臨床試驗熱圖

第6章：全球癌症疫苗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依適應症類型（前列腺癌、黑色素瘤、膀胱癌、子宮頸癌
    • 依疫苗類型（預防性癌症疫苗、治療性癌症疫苗）
    • 依技術類型（重組癌症疫苗、全細胞癌症疫苗、病毒載體和 DNA 癌症疫苗）
    • 按公司分類（2024）
    • 按地區
  • 市場地圖

第7章：北美癌症疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第8章：歐洲癌症疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章：亞太地區癌症疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第10章：南美癌症疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章：中東和非洲癌症疫苗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 12 章：市場動態

  • 驅動程式
  • 挑戰

第13章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 併購

第 14 章： 大環境分析

第 15 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 16 章：競爭格局

  • Merck & Co., Inc.
  • GSK plc
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies.
  • Ferring BV
  • Amgen, Inc.
  • Moderna, Inc.
  • Sanofi SA
  • AstraZeneca Pharmaceuticals LP
  • Bristol-Myers Squibb Company

第 17 章：策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 15887

Global Cancer Vaccine Market was valued at USD 8.32 billion in 2024 and is expected to reach USD 14.15 billion in the forecast period with a CAGR of 9.21% through 2030. A cancer vaccine is a type of immunotherapy that aims to stimulate the immune system to recognize and attack cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines are designed to treat or prevent cancer by leveraging the body's own immune response. The concept behind cancer vaccines is to present the immune system with specific molecules or antigens found on the surface of cancer cells. These antigens are often unique to cancer cells or are more abundant on cancer cells compared to normal cells. By exposing the immune system to these antigens, the goal is to prime immune cells to identify and destroy cancer cells while sparing healthy cells.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 8.32 Billion
Market Size 2030USD 14.15 Billion
CAGR 2025-20309.21%
Fastest Growing SegmentRecombinant Cancer Vaccines
Largest MarketNorth America

The success of immunotherapies, including immune checkpoint inhibitors and CAR-T cell therapies, has generated interest and confidence in the potential of cancer vaccines. These advancements have highlighted the role of the immune system in targeting cancer cells, driving further research and investment in cancer vaccines. Advances in genomics, proteomics, and bioinformatics have enabled a deeper understanding of tumor biology and the identification of potential vaccine targets. These technological innovations have accelerated the discovery and development of cancer vaccines. The concept of combining different treatment modalities, such as vaccines with immune checkpoint inhibitors or chemotherapy, has gained traction. Combination therapies have the potential to enhance treatment efficacy and overcome resistance mechanisms. Various global health organizations and initiatives have highlighted the importance of cancer prevention and treatment. These initiatives contribute to increased awareness and funding for cancer vaccine research and development.

Key Market Drivers

Growing Demand of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors have become a cornerstone in modern cancer immunotherapy, offering a transformative approach to treating malignancies that were once considered difficult to manage. These drugs work by targeting checkpoint proteins such as PD-1, PD-L1, and CTLA-4, which act as regulatory switches on immune cells. By blocking these proteins, immune checkpoint inhibitors restore the immune system's ability to detect and destroy cancer cells. According to a 2024 study published in Nature Reviews Drug Discovery, over 40 FDA-approved indications now exist for checkpoint inhibitors, covering more than 20 cancer types. This rising number of approvals demonstrates the expanding clinical utility and acceptance of these therapies.

One of the most compelling aspects of immune checkpoint inhibitors is their ability to produce durable and, in some cases, complete responses in patients with advanced-stage cancers. Recent data from the American Association for Cancer Research (AACR) reveals that five-year survival rates for patients with metastatic melanoma have improved from under 10% to nearly 35% with checkpoint inhibitor therapy. These outcomes are especially significant for patients who had exhausted conventional treatment options. The success stories from checkpoint inhibitor therapies have intensified the focus on immunotherapeutic approaches, including cancer vaccines, which can potentially synergize with these agents to produce even more powerful immune responses.

Checkpoint inhibitors are increasingly being used in combination therapy regimens to overcome resistance mechanisms and broaden their efficacy. Clinical trials are currently exploring over 1,000 combination strategies globally, many of which involve pairing checkpoint inhibitors with cancer vaccines. The rationale behind such combinations lies in their complementary mechanisms-vaccines prime the immune system to recognize tumor-specific antigens, while checkpoint inhibitors unleash T cells to eliminate the identified cancer cells. This integrated approach is driving deeper and more sustained responses, particularly in tumors with low immunogenicity that may not respond well to monotherapies.

The growing demand for immune checkpoint inhibitors is not only driving innovation in therapeutic strategies but also reinforcing the role of cancer vaccines as a critical component of immuno-oncology pipelines. As researchers strive to enhance treatment precision and personalization, vaccines are being developed to target neoantigens identified through next-generation sequencing. The success and continued development of checkpoint inhibitors have built a robust foundation of scientific, clinical, and commercial support for immunotherapies. This momentum is expected to further accelerate interest and investment in cancer vaccines, which are increasingly seen as essential components of comprehensive cancer immunotherapy regimens.

Key Market Challenges

Complexity of Cancer Immunology

Cancer immunology involves the intricate interplay between cancer cells and the immune system, and understanding and manipulating this interaction for therapeutic purposes is no small task. Cancers are highly heterogeneous, meaning that they can have diverse populations of cells with distinct genetic and antigenic profiles. Identifying the right antigens to target with a vaccine becomes challenging, as a one-size-fits-all approach may not be effective. Cancer cells can develop mechanisms to evade immune detection and attack. They can downregulate antigens, express inhibitory molecules, or create an immunosuppressive microenvironment. Developing vaccines that overcome these strategies is complex.

Selecting the most appropriate antigens for targeting is a challenge. Not all tumor antigens are equally effective at inducing a strong immune response, and the wrong choice can result in inadequate therapeutic outcomes. The immune system is designed to avoid attacking healthy cells. Overcoming immune tolerance mechanisms while avoiding autoimmune reactions is a delicate balance that must be considered in vaccine design. Ensuring that the vaccine itself is immunogenic and can stimulate a robust immune response is crucial. Some tumors may have a suppressive effect on the immune system, making it difficult to generate a response. Identifying reliable biomarkers that predict which patients will respond positively to a cancer vaccine is a challenge. Responders and non-responders can have varied immune profiles, and finding consistent predictive markers can be difficult.

Key Market Trends

Collaborations and Partnerships

The complex nature of cancer research, vaccine development, and clinical trials often necessitates collaboration among various stakeholders to accelerate progress, share expertise, and pool resources. Developing effective cancer vaccines requires expertise in various fields, including immunology, oncology, virology, genetics, and more. Collaborations allow researchers and organizations to bring together experts from different disciplines to tackle complex challenges. Collaborations enable the sharing of resources, such as research facilities, laboratories, equipment, and reagents. This can reduce costs and accelerate the research and development process. Partnerships provide access to cutting-edge technologies and platforms that individual organizations might not have. This can streamline vaccine development and improve research capabilities.

In-depth understanding of cancer biology and immunology requires access to vast amounts of data. Collaborations allow for data sharing, analysis, and integration, facilitating better insights into vaccine targets and mechanisms. Running clinical trials for cancer vaccines often requires collaboration among multiple institutions and hospitals. Partnerships can facilitate patient recruitment, trial logistics, and data collection. Collaborations can attract funding from various sources, including government agencies, private investors, philanthropic organizations, and venture capital firms. This financial support can drive research and development efforts. Partnerships with pharmaceutical companies can help bring cancer vaccines to market more effectively, leveraging established distribution channels, sales teams, and marketing resources.

Key Market Players

  • Merck & Co., Inc.
  • GSK plc
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies.
  • Ferring B.V.
  • Amgen, Inc.
  • Moderna, Inc.
  • Sanofi SA
  • AstraZeneca Pharmaceuticals LP
  • Bristol-Myers Squibb Company

Report Scope:

In this report, the Global Cancer Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cancer Vaccine Market, By Indication Type:

  • Prostate Cancer
  • Melanoma
  • Bladder Cancer
  • Cervical Cancer

Cancer Vaccine Market, By Vaccine Type:

  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines

Cancer Vaccine Market, By Technology Type:

  • Recombinant Cancer Vaccines
  • Whole-Cell Cancer Vaccines
  • Viral Vector and DNA Cancer Vaccines

Cancer Vaccine Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Vaccine Market.

Available Customizations:

Global Cancer Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trials Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Type
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Cancer Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication Type (Prostate Cancer, Melanoma, Bladder Cancer, Cervical Cancer
    • 6.2.2. By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines)
    • 6.2.3. By Technology Type (Recombinant Cancer Vaccines, Whole-Cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines)
    • 6.2.4. By Company (2024)
    • 6.2.5. By Region
  • 6.3. Market Map

7. North America Cancer Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication Type
    • 7.2.2. By Vaccine Type
    • 7.2.3. By Technology Type
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Cancer Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication Type
        • 7.3.1.2.2. By Vaccine Type
        • 7.3.1.2.3. By Technology Type
    • 7.3.2. Mexico Cancer Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication Type
        • 7.3.2.2.2. By Vaccine Type
        • 7.3.2.2.3. By Technology Type
    • 7.3.3. Canada Cancer Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication Type
        • 7.3.3.2.2. By Vaccine Type
        • 7.3.3.2.3. By Technology Type

8. Europe Cancer Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication Type
    • 8.2.2. By Vaccine Type
    • 8.2.3. By Technology Type
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Cancer Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication Type
        • 8.3.1.2.2. By Vaccine Type
        • 8.3.1.2.3. By Technology Type
    • 8.3.2. Germany Cancer Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication Type
        • 8.3.2.2.2. By Vaccine Type
        • 8.3.2.2.3. By Technology Type
    • 8.3.3. United Kingdom Cancer Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication Type
        • 8.3.3.2.2. By Vaccine Type
        • 8.3.3.2.3. By Technology Type
    • 8.3.4. Italy Cancer Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication Type
        • 8.3.4.2.2. By Vaccine Type
        • 8.3.4.2.3. By Technology Type
    • 8.3.5. Spain Cancer Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication Type
        • 8.3.5.2.2. By Vaccine Type
        • 8.3.5.2.3. By Technology Type

9. Asia-Pacific Cancer Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication Type
    • 9.2.2. By Vaccine Type
    • 9.2.3. By Technology Type
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Cancer Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication Type
        • 9.3.1.2.2. By Vaccine Type
        • 9.3.1.2.3. By Technology Type
    • 9.3.2. India Cancer Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication Type
        • 9.3.2.2.2. By Vaccine Type
        • 9.3.2.2.3. By Technology Type
    • 9.3.3. South Korea Cancer Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication Type
        • 9.3.3.2.2. By Vaccine Type
        • 9.3.3.2.3. By Technology Type
    • 9.3.4. Japan Cancer Vaccine Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Indication Type
        • 9.3.4.2.2. By Vaccine Type
        • 9.3.4.2.3. By Technology Type
    • 9.3.5. Australia Cancer Vaccine Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Indication Type
        • 9.3.5.2.2. By Vaccine Type
        • 9.3.5.2.3. By Technology Type

10. South America Cancer Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication Type
    • 10.2.2. By Vaccine Type
    • 10.2.3. By Technology Type
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Cancer Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication Type
        • 10.3.1.2.2. By Vaccine Type
        • 10.3.1.2.3. By Technology Type
    • 10.3.2. Argentina Cancer Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication Type
        • 10.3.2.2.2. By Vaccine Type
        • 10.3.2.2.3. By Technology Type
    • 10.3.3. Colombia Cancer Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication Type
        • 10.3.3.2.2. By Vaccine Type
        • 10.3.3.2.3. By Technology Type

11. Middle East and Africa Cancer Vaccine Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication Type
    • 11.2.2. By Vaccine Type
    • 11.2.3. By Technology Type
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Cancer Vaccine Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Indication Type
        • 11.3.1.2.2. By Vaccine Type
        • 11.3.1.2.3. By Technology Type
    • 11.3.2. Saudi Arabia Cancer Vaccine Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Indication Type
        • 11.3.2.2.2. By Vaccine Type
        • 11.3.2.2.3. By Technology Type
    • 11.3.3. UAE Cancer Vaccine Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Indication Type
        • 11.3.3.2.2. By Vaccine Type
        • 11.3.3.2.3. By Technology Type

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Product Launches
  • 13.3. Mergers & Acquisitions

14. PESTLE Analysis

15. Porter's Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Product

16. Competitive Landscape

  • 16.1. Merck & Co., Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. GSK plc
  • 16.3. Dendreon Pharmaceuticals LLC.
  • 16.4. Dynavax Technologies.
  • 16.5. Ferring B.V.
  • 16.6. Amgen, Inc.
  • 16.7. Moderna, Inc.
  • 16.8. Sanofi SA
  • 16.9. AstraZeneca Pharmaceuticals LP
  • 16.10. Bristol-Myers Squibb Company

17. Strategic Recommendations

18. About us & Disclaimer